Search

The prospect of unified Democratic control in Washington is cause for some unease in an industry that has, for years, aligned closely with Republicans. Indeed, President-elect Obama and congressional Democrats [...]

[ILLUSTRATION OMITTED] His healthcare plan calls for allowing drug reimportation and direct government negotiation of drug prices with companies that, he says, 'benefit most from the status quo, and in [...]

[ILLUSTRATION OMITTED] Pharmaceutical companies seem to be holding the line on grants for now, but with intense pressure from officials, academia and increasingly, the medical community, not to mention their [...]

[ILLUSTRATION OMITTED] Direct-to-consumer advertising is set for a sea-change, as marketers embrace more targeted and digital-heavy media plans to push more modest products and fewer mega-blockbusters through--not that you'd know [...]

[ILLUSTRATION OMITTED] When the going got tough, Merck got back to basics. Today, only a few years after a toxic combination of high-profile drug failures and the Vioxx safety debacle [...]

[ILLUSTRATIONS OMITTED] A cautious FDA sweating product safety issues and going slow on new approvals. An election year in which healthcare tops the agenda. Increased oversight, increasingly demanding payors and [...]

[ILLUSTRATION OMITTED] As big pharma binges on biotechs to feed anemic pipelines, at least one major player isn't getting indigestion. Wyeth has been in the biotech game for more than [...]

Innovative new oncology drugs and an increase in prescribing volume due to Medicare Part D drove a rebound in US prescription drug growth of 8.3% for 2006, up from 5.4% [...]

It's been 10 years since it was first 'time for Claritin,' and DTC advertising as we know it was born. A decade after the FDA issued its draft guidance on [...]

Hearings, hearings and more hearings on the dastardly doings of the pharmaceutical industry will be the order of the day for a Democratic Congress, Washington insiders say. While congressional Dems [...]

With sales forces feeling the pinch from physicians, Merck is turning to technology to realize efficiencies and help reps hit their targets. The firm has deployed tablet PCs to 5,000 [...]

Pharmaceutical companies spent $518 million advertising to doctors in 2005, according to research firm PERQ/HCI, and another $1.6 billion on magazine ads aimed at consumers, according to TNS Media Intelligence. [...]

The medical advertising and communications behemoth Publicis Healthcare Communications Group saw strong organic growth this year, expanding its business with core clients Sanofi-Aventis and AstraZeneca as it rebranded one of [...]

Consumer drug advertising is back--if it was ever really gone--nattily attired in a starched lab coat. After an apocalyptic post-Vioxx pause, when many marketers folded their wallets, held their breaths [...]

While pharma's biggest players continue to wear their poker faces in the game of sales-force contraction, Wyeth has boldly laid its cards on the table, announcing a creative solution to [...]

Analysts are hopeful that both companies and consumers will come out ahead with the implementation of Medicare Part D, but the realignment will take all parties into uncharted waters. For [...]

National TV advertising may be losing some of its luster, but disease-specific cable and local broadcasts beckon, offering advertisers a cheaper and more targeted means of reaching patient communities. Leading [...]

DTC OUTLOOK Pharmaceutical companies are facing increasing pressure from Washington, the media, the public and from fellow pharma chiefs to advertise to consumers in a more responsible way, conveying risks [...]

The crisis over the safety of COX-2 inhibitors is almost certainly the most severe to hit the industry in decades. At stake are the reputations not only of Merck and [...]

Much of Big Pharma breathed a sigh of relief at the news of President Bush's re-election, as Kerry and Edwards, two of the industry's harshest critics, were sent back to [...]

'Most companies, when they're launching a product in primary care, will advertise to PAs and NPs,' says Carla Duryee, who heads marketing to midlevel practitioners for Sanofi-Aventis. 'But very few [...]

Pharmaceutical advertising doesn't exactly have the wildest reputation within the marketing business, but you could hardly want for a more exciting environment these days, as agencies buffeted by wave upon [...]

What really keeps the custodians of the world's best-selling prescription drug awake at night? It's not so much the competition, nor is it patent exclusivity. What worries the relationship marketers [...]

Genentech's head of corporate relations. Mary Stutts, reckons the drug industry could do with fewer celebrity endorsers and more heroes. That's why Napoleone 'Napo' Ferrara is the new face of [...]

In recent months, Artificial Intelligence (AI) has had, and will continue to have, a dramatic impact on Higher Education (HE). A study conducted by researchers at a leading university in Australia surveyed 30 of their teaching staff, drawn predominantly from their teaching academy, and interviewed eight of them regarding the impact of AI on HE. Data were analyzed using the procedures of Inductive Thematic Analysis and revealed a lack of any homogenous sentiment around AI in HE and much ambiguity regarding best practice regarding recent technological developments. The results indicate concerns exist around concepts relating to academic integrity, however, these concerns may be exaggerated. Almost half of the participants indicated they were using AI within their teaching roles with the most common design change being modifications to assessments. Less than a quarter of staff agreed the university has adequately equipped them for AI, and more than three quarters indicated they would like support. They unanimously assumed the technology will improve. Keeping in mind universities’ obligation to serve students by preparing them for industry, it is vitally important that the HE sector stays informed of developments in AI and commit to ongoing research and discussions regarding best practice in response to AI. However, anything regarding AI and future developments will be extremely difficult to predict.

Thomson's $135 million sale of its Medical Economics, veterinary and dental units has sent ripples through the sluggish medical publishing industry, giving Advanstar greater entree with advertisers through several of [...]

In an ugly season for medical advertising, a wave of intra-agency consolidation has roiled the agency world and sent smaller shops reeling as the big boys band together. Matthew Arnold [...]

Direct marketing has yet to live up to its potential in the pharmaceutical sector, but as the burden of pharmaceutical marketers shifts from acquiring patients to improving compliance and physicians [...]

Despite mounting evidence that DTC advertising provides a public health benefit by educating consumers, critics won't be quieted. Matthew Arnold looks at how the industry might better mold its message [...]

Determining the return on internet marketing investment is one of marketers' toughest challenges. Senior reporter Matthew Arnold looks at this issue, as well as the potential of e-detailing and consolidation [...]